Nasdaq
$7.32▼ 0.14%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $999.8MShares out 1.400M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
8- 1d agoPre-market26.10.23 20:306-KKey event#●●●#●●●
Immatics N.V.Bullish
Immatics N.V. announced updated Phase 1 clinical data for IMA203CD8 in 98 patients with advanced solid tumors as of August 7, 2026. Among 90 evaluable patients, the objective response rate (ORR) was 51% with a confirmed ORR (cORR) of 41%, while gynecologic cancer patients showed an ORR of 60%. The company is currently enrolling uterine cancer patients and plans to initiate a Phase 1/2 trial for pediatric cancers in the first half of 2027.…more
$7.32-0.14%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.27After-hours26.08.28 05:004Ownership
Immatics N.V.
Major shareholders of Immatics N.V., including Perceptive Advisors LLC and affiliated funds, filed an SEC Form 4 on August 26, 2026, reporting changes in their beneficial ownership of company securities. This filing formalizes the shift in equity holdings by insiders and major stakeholders, allowing investors to track their recent trading activity.…more
$7.32-0.14%vs prev closeView filingShare - 8.27After-hours26.08.28 05:00SCHEDULE 13D/AOwnership
Immatics N.V.
Perceptive Advisors LLC filed a SCHEDULE 13D/A on August 27, 2026, to update its beneficial ownership status in Immatics N.V. The filing details changes in the investment firm's stake and its purpose of holding shares in the company.…more
$7.32-0.14%vs prev closeView filingShare
7 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 1d agoClosed26.10.24 15:30#●●●#●●●
Immatics Presents Clinical Data for PRAME-Targeting Therapies at ESMO 2026…more
Immatics announced encouraging interim clinical data for its PRAME-targeting therapies, IMA402 and IMA203CD8, at the 2026 ESMO Annual Meeting. As these are preliminary results from ongoing clinical trials, the announcement is viewed as neutral regarding immediate stock price impact.…more
$7.32-0.14%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 8.25Pre-market26.08.25 20:05
●●●●●●●● ●●●●● ●●●●●●
Immatics has announced a $150 million underwritten offering of ordinary shares and pre-funded warrants. The move is expected to result in shareholder dilution as the company raises capital.…more
$7.32-0.14%vs prev closeShareBenzinga - 8.18Pre-market26.08.18 20:33
●●●●●●●● ●●●●● ●●●●●●
Immatics reported a Q2 loss per share of $0.53 and revenue of $10.63 million, both missing analyst expectations. While revenue grew compared to the previous year, the wider-than-expected losses reflect a disappointing quarterly performance.…more
$7.32-0.14%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report